Navigation Links
Cumberland Pharmaceuticals Reports Third Quarter Financial Results
Date:11/5/2013

NASHVILLE, Tenn., Nov. 5, 2013 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced third quarter 2013 financial results.

Net Revenue:  For the three months ended September 30, 2013, net revenue was $6.5 million compared to $12.5 million for the prior year period.  Net revenue was $3.8 million for Acetadote, $2.2 million for Kristalose and $0.5 million for Caldolor.

For the nine months ended September 30, 2013, net revenue was $23.9 million compared with $35.2 million for the nine months ended September 30, 2012.

Operating Expenses:  Total operating expenses for the three months ended September 30, 2013, were $8.0 million compared to $9.6 million during the prior year period. 

For the nine months ended September 30, 2013, operating expenses were $25.2 million compared to $29.6 million for the prior year period.

Net Income (Loss):  Net income (loss) attributable to common shareholders for the three months ended September 30, 2013, was $(0.8) million, or $(0.04) per diluted share.

For the nine months ended September 30, 2013, net income attributable to common shareholders was $(0.6) million, or $(0.03) per diluted share.

Cash Flow: Operating cash flows for the nine months ended September 30, 2013, were $0.9 million, compared to $5.1 million, for the prior year period. 

Balance Sheet:  As of September 30, 2013, Cumberland had $65.2 million in cash and marketable securities, with approximately $46.0 million in cash and equivalents and $19.2 million in marketable securities.  Total assets at September 30, 2013, were $91.9 million.

"The recent addition of Omeclamox-Pak reflects our commitment to the expansion of our prod
'/>"/>

SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Cumberland Pharmaceuticals Reports First Quarter 2012 Financial Results
2. Cumberland Pharmaceuticals To Present At The 2012 Wells Fargo Securities Healthcare Conference In Boston
3. Cumberland Pharmaceuticals To Announce Second Quarter 2012 Financial Results On August 2, 2012
4. Cumberland Pharmaceuticals Reports Second Quarter 2012 Financial Results
5. Cumberland Pharmaceuticals to Present at the UBS Global Life Sciences Conference in New York
6. Cumberland Pharmaceuticals Reports Third Quarter 2012 Financial Results
7. Cumberland Emerging Technologies Expands Life Sciences Center
8. Cumberland Pharmaceuticals And PT. SOHO Industri Pharmasi enter Into Exclusive Licensing Agreement For Caldolor In Indonesia
9. Cumberland Pharmaceuticals To Announce 2012 Year End Financial Results On February 28, 2013
10. Cumberland Pharmaceuticals Reports 2012 Annual Financial Results
11. Cumberland Pharmaceuticals To Announce First Quarter 2013 Financial Results On May 2, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... SETAUKET, N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, ... where its Phase I trial of Lixte,s lead compound, LB‑100, ... institutions. John S. Kovach , M.D., the ... was planned to be completed at a single site. Accrual ...
(Date:1/23/2015)... , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... Directors has approved a share repurchase program. The open-ended ... million of Mallinckrodt plc ordinary shares. ... remain top priorities as we continue to pursue a ...
(Date:1/22/2015)... 22, 2015  ViewRay™, a privately held medical device company, ... distributor agreement with ITOCHU Corporation (Tokyo Stock Exchange TYO: ... the treatment of cancer in Japan ... world,s first and only MRI-guided radiation therapy system that ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2
... sodium injection) were also ... within 90 days-, BRIDGEWATER, N.J., Dec 10 ... total hospital,direct medical costs associated with VTE treatment are ... the use of low-molecular weight heparin,(LMWH) vs. unfractionated heparin ...
... 10 Alfacell Corporation,(Nasdaq: ACEL ) today reported ... The company recorded a net loss of approximately ... for the fiscal quarter ended Oct. 31,compared to a ... and diluted,common share, for the first quarter of fiscal ...
Cached Medicine Technology:Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH) 2Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH) 3Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH) 4Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH) 5Alfacell Reports Financial Results for First Quarter of Fiscal 2008 2Alfacell Reports Financial Results for First Quarter of Fiscal 2008 3Alfacell Reports Financial Results for First Quarter of Fiscal 2008 4Alfacell Reports Financial Results for First Quarter of Fiscal 2008 5
(Date:1/22/2015)... 22, 2015 The Incredible Bulk is a ... to increase lean muscle by up to 30lbs in less ... attention of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , ... a step-by-step, scientific diet formula that allows the body to ...
(Date:1/22/2015)... 22, 2015 Blue Cross and Blue Shield ... exemplify what it means to “Live Fearless.” , ... to share their stories about how they or someone they ... others by living in the moment. By telling these types ...
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District of ... C.R. Bard, Inc. in that proceeding’s first bellwether trial. In ... request for a new trial after finding that C.R. Bard ...
(Date:1/22/2015)... A new white paper by The ... in the long-term care environment as well as provides ... The paper, “The Power of Person-Centeredness in Long-Term Care: ... of the patient, resident and family experience in long-term ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Autocarinsurancebest.com has released ... purchasing a commercial auto insurance policy . , Auto ... their vehicles. It is no longer necessary to call an ... are now available online on a single website: http://autocarinsurancebest.com/ ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Commercial Auto Insurance Provides Several Important Features! 2
... , THURSDAY, April 21 (HealthDay News) -- Long-term ... condition known as eczema doesn,t cause any major negative side ... concerned about the use of corticosteroid creams or lotions applied ... eczema in children, the researchers explained. The most common fear ...
... Data and Safety Monitoring Committee (DSMC) has determined that ... in addition to a standard chemotherapy regimen for advanced ... progression-free survival than patients on the same chemotherapy regimen ... 1,000 patients who had advanced, hormone-refractory prostate cancer were ...
... happiest countries and happiest U.S. states tend to have the ... of Warwick, Hamilton College in New York and the Federal ... titled Dark Contrasts: The Paradox of High Rates of Suicide ... Journal of Economic Behavior & Organization . It uses ...
... Health at the Mailman School of Public Health report evidence ... and deficits in IQ and working memory at age seven. ... of prenatal chlorpyrifos exposure on cognitive development at the time ... Health Perspectives . Until banned for indoor residential ...
... among different breast cancer treatment options make smarter choices when ... than all at once, as is customary, a University of ... who aren,t good with numbers have a harder time understanding ... says Brian Zikmund-Fisher, assistant professor at the U-M School of ...
... ,Press registration is now open for Transcatheter Valve ... at http://www.tvtconference.com/conference/press-registration.html . TVT is a unique ... diagnostic and therapeutic options for the treatment of ... Late Breaking Clinical Data, Emerging Technologies: ...
Cached Medicine News:Health News:Corticosteroid Creams Safe for Kids With Eczema: Study 2Health News:Phase 3 trial finds no benefit from atrasentan added to chemo for advanced prostate cancer 2Health News:Happiest places have highest suicide rates says new research 2Health News:Happiest places have highest suicide rates says new research 3Health News:Prenatal exposure to common insecticide linked to decreases in cognitive functioning at age 7 2Health News:Presenting cancer treatment options in small doses yields smarter choices 2
... the iQ®200 Automated Urine Microscopy Analyzer ... Automated Urine Chemistry Analyzer (AX-4280) to ... microscopic analysis. The iQ200 uses Auto-Particle ... network, to classify and quantitate twelve ...
... The Sysmex UF-100 is designed to ... microscopic analysis. It combines the superior ... automated urine sample analysis. Continuous sampling ... the rack-based autosamplers, streamlining sample processing in ...
... easy to use Ambulatory Urodynamic recorder which ... practising urologists as an invaluable aid in ... The system offers the possibility to measure ... natural bladder filling, extented over a longer ...
Data review and analysis is carried out with the Acquidata Uromac software already supplied with Acquidata Uromac Lab based urodynamics systems...
Medicine Products: